Direct and indirect effects of rotavirus vaccination: Comparing predictions from transmission dynamic models

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Pitzer, Virginia E ^a,b,c   Atkins, Katherine E ^c   de Blasio, Birgitte Freiesleben ^d,e   van Effelterre, Thierry ^f   Atchison, Christina J ^g   Harris, John P ^h   Shim, Eunha ⁱ   Galvani, Alison P ^c   Edmunds, W John ^g   Viboud, Cécile ^b   Patel, Manish M ^j   Grenfell, Bryan T ^a,b   Parashar, Umesh D ^j   Lopman, Ben A ^j  

^a PRINCETON UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c YALE UNIVERSITY   (United States)

^d UNIVERSITY OF OSLO   (Norway)

^e NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^f GSK   (Belgium)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^h PUBLIC HEALTH ENGLAND   (United Kingdom)

ⁱ UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^j NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; EPIDEMIC; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INNATE IMMUNITY; OUTCOME ASSESSMENT; PREDICTION; PRESCHOOL CHILD; ROTAVIRUS INFECTION; TREATMENT DURATION; TREATMENT RESPONSE; VACCINATION; VIRAL GASTROENTERITIS; VIRUS TRANSMISSION;

COMPUTATIONAL BIOLOGY; MODELS, STATISTICAL; ROTAVIRUS; ROTAVIRUS INFECTIONS; TIME FACTORS; VACCINATION;

EID: 84865057470     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042320     Document Type: Article

References (50)

1. Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, et al. (2011) Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. Pediatr Infect Dis J 30: S25-29.
2. Curns AT, Steiner CA, Barrett M, Hunter K, Wilson E, et al. (2010) Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 201: 1617-1624.
3. Paulke-Korinek M, Rendi-Wagner P, Kundi M, Kronik R, Kollaritsch H, (2011) Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in austrian children. Pediatr Infect Dis J 29: 319-323.
4. Tate JE, Cortese MM, Payne DC, Curns AT, Yen C, et al. (2011) Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data. Pediatr Infect Dis J 30: S56-60.
5. Tate JE, Panozzo CA, Payne DC, Patel MM, Cortese MM, et al. (2009) Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 124: 465-471.
6. Yen C, Armero Guardado JA, Alberto P, Rodriguez Araujo DS, Mena C, et al. (2011) Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. Pediatr Infect Dis J 30: S6-S10.
7. Atchison C, Lopman B, Edmunds WJ, (2010) Modelling the seasonality of rotavirus disease and the impact of vaccination in England and Wales. Vaccine 28: 3118-3126.
8. Atkins KE, Shim E, Pitzer VE, Galvani AP, (2012) Impact of rotavirus vaccination on epidemiological dynamics in England and Wales. Vaccine 30: 552-564.
9. de Blasio BF, Kasymbekova K, Flem E, (2010) Dynamic model of rotavirus transmission and the impact of rotavirus vaccination in Kyrgyzstan. Vaccine 28: 7923-7932.
10. Pitzer VE, Viboud C, Simonsen L, Steiner C, Panozzo CA, et al. (2009) Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics. Science 325: 290-294.
11. Shim E, Feng Z, Martcheva M, Castillo-Chavez C, (2006) An age-structured epidemic model of rotavirus with vaccination. J Math Biol 53: 719-746.
12. Shim E, Galvani AP, (2009) Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination. Vaccine 27: 4025-4030.
13. Van Effelterre T, Soriano-Gabarro M, Debrus S, Claire Newbern E, Gray J, (2010) A mathematical model of the indirect effects of rotavirus vaccination. Epidemiol Infect 138: 884-897.
14. Fischer TK, Valentiner-Branth P, Steinsland H, Perch M, Santos G, et al. (2002) Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, west Africa. J Infect Dis 186: 593-597.
15. Grinstein S, Gomez JA, Bercovich JA, Biscotti EL, (1989) Epidemiology of rotavirus infection and gastroenteritis in prospectively monitored Argentine families with young children. Am J Epidemiol 130: 300-308.
16. Moulton LH, Staat MA, Santosham M, Ward RL, (1998) The protective effectiveness of natural rotavirus infection in an American Indian population. J Infect Dis 178: 1562-1566.
17. Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, et al. (1996) Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 335: 1022-1028.
18. Ward RL, Bernstein DI, (1994) Protection against rotavirus disease after natural rotavirus infection. US Rotavirus Vaccine Efficacy Group. J Infect Dis 169: 900-904.
19. Ward RL, Bernstein DI, Shukla R, McNeal MM, Sherwood JR, et al. (1990) Protection of adults rechallenged with a human rotavirus. J Infect Dis 161: 440-445.
20. Ward RL, Clemens JD, Knowlton DR, Rao MR, van Loon FP, et al. (1992) Evidence that protection against rotavirus diarrhea after natural infection is not dependent on serotype-specific neutralizing antibody. J Infect Dis 166: 1251-1257.
21. White LJ, Buttery J, Cooper B, Nokes DJ, Medley GF, (2008) Rotavirus within day care centres in Oxfordshire, UK: characterization of partial immunity. J R Soc Interface.
22. UNAIDS/WHO/SACEMA Expert Group on Modelling the Impact and Cost of Male Circumcision for HIV Prevention (2009) Male circumcision for HIV prevention in high HIV prevalence settings: what can mathematical modelling contribute to informed decision making? PLoS Med 6: e1000109.
23. Brisson M, Edmunds WJ, (2006) Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making 26: 434-446.
24. Conlan AJ, Rohani P, Lloyd AL, Keeling M, Grenfell BT, (2010) Resolving the impact of waiting time distributions on the persistence of measles. J R Soc Interface 7: 623-640.
25. Halloran ME, Ferguson NM, Eubank S, Longini IM Jr, Cummings DA, et al. (2008) Modeling targeted layered containment of an influenza pandemic in the United States. Proc Natl Acad Sci U S A 105: 4639-4644.
26. Van de Velde N, Brisson M, Boily MC, (2010) Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. Vaccine 28: 5473-5484.
27. Wall PG, de Louvois J, Gilbert RJ, Rowe B, (1996) Food poisoning: notifications, laboratory reports, and outbreaks-where do the statistics come from and what do they mean? Commun Dis Rep CDR Rev 6: R93-100.
28. Wheeler JG, Sethi D, Cowden JM, Wall PG, Rodrigues LC, et al. (1999) Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance. The Infectious Intestinal Disease Study Executive. BMJ 318: 1046-1050.
29. Tam CC, Rodrigues LC, Viviani L, Dodds JP, Evans MR, et al. (2012) Longitudinal study of infectious intestinal disease in the UK (IID2 study): incidence in the community and presenting to general practice. Gut 61: 69-77.
30. Halloran ME, Haber M, Longini IM Jr, (1992) Interpretation and estimation of vaccine efficacy under heterogeneity. Am J Epidemiol 136: 328-343.
31. Smith PG, Rodrigues LC, Fine PE, (1984) Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int J Epidemiol 13: 87-93.
32. Mossong J, Hens N, Jit M, Beutels P, Auranen K, et al. (2008) Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 5: e74.
33. Office of National Statistics. Age Structure of England and Wales (2009) Available: http://www.neighbourhood.statistics.gov.uk/HTMLDocs/dvc2/EWPyramid.html. Accessed 2011 Nov 14.
34. Linhares AC, Velazquez FR, Perez-Schael I, Saez-Llorens X, Abate H, et al. (2008) Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 371: 1181-1189.
35. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, et al. (2006) Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354: 11-22.
36. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, et al. (2007) Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 370: 1757-1763.
37. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, et al. (2006) Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354: 23-33.
38. Vesikari T, Karvonen A, Korhonen T, Espo M, Lebacq E, et al. (2004) Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 22: 2836-2842.
39. Atchison CJ, Tam CC, Hajat S, van Pelt W, Cowden JM, et al. (2009) Temperature-dependent transmission of rotavirus in Great Britain and The Netherlands. Proc Biol Sci 277: 933-942.
40. Braeckman T, Van Herck K, Raes M, Vergison A, Sabbe M, et al. (2011) Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J 30: S21-24.
41. Curns AT, Panozzo CA, Tate JE, Payne DC, Patel MM, et al. (2011) Remarkable postvaccination spatiotemporal changes in United States rotavirus activity. Pediatr Infect Dis J 30: S54-55.
42. Safadi MA, Berezin EN, Munford V, Almeida FJ, de Moraes JC, et al. (2010) Hospital-based surveillance to evaluate the impact of rotavirus vaccination in Sao Paulo, Brazil. Pediatr Infect Dis J 29: 1019-1022.
43. Lopman BA, Curns AT, Yen C, Parashar UD, (2011) Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 204: 980-986.
44. Macartney KK, Porwal M, Dalton D, Cripps T, Maldigri T, et al. (2011) Decline in rotavirus hospitalisations following introduction of Australia's national rotavirus immunisation programme. J Paediatr Child Health 47: 266-270.
45. Payne DC, Staat MA, Edwards KM, Szilagyi PG, Weinberg GA, et al. (2011) Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis 53: 245-253.
46. Pitman R, Carroll S, (2010) Handling uncertainty in dynamic transmission models. Vaccine 29: 3827 author reply 3828.
47. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, et al. (2010) Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet.
48. Correia JB, Patel MM, Nakagomi O, Montenegro FM, Germano EM, et al. (2010) Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis 201: 363-369.
49. de Palma O, Cruz L, Ramos H, de Baires A, Villatoro N, et al. (2010) Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ 340: c2825.
50. Justino MC, Linhares AC, Lanzieri TM, Miranda Y, Mascarenhas JD, et al. (2011) Effectiveness of the Monovalent G1P[8] Human Rotavirus Vaccine Against Hospitalization for Severe G2P[4] Rotavirus Gastroenteritis in Belem, Brazil. Pediatr Infect Dis J 30: 396-401.